239 related articles for article (PubMed ID: 35105803)
21. Targeting Oncogenic Super Enhancers in MYC-Dependent AML Using a Small Molecule Activator of NR4A Nuclear Receptors.
Call SG; Duren RP; Panigrahi AK; Nguyen L; Freire PR; Grimm SL; Coarfa C; Conneely OM
Sci Rep; 2020 Feb; 10(1):2851. PubMed ID: 32071334
[TBL] [Abstract][Full Text] [Related]
22. Ferritinophagy is required for the induction of ferroptosis by the bromodomain protein BRD4 inhibitor (+)-JQ1 in cancer cells.
Sui S; Zhang J; Xu S; Wang Q; Wang P; Pang D
Cell Death Dis; 2019 Apr; 10(5):331. PubMed ID: 30988278
[TBL] [Abstract][Full Text] [Related]
23. miR-766-5p Targets Super-Enhancers by Downregulating CBP and BRD4.
Gen Y; Muramatsu T; Inoue J; Inazawa J
Cancer Res; 2021 Oct; 81(20):5190-5201. PubMed ID: 34353856
[TBL] [Abstract][Full Text] [Related]
24. A Combination of an Antimitotic and a Bromodomain 4 Inhibitor Synergistically Inhibits the Metastatic MDA-MB-231 Breast Cancer Cell Line.
Mqoco T; Stander A; Engelbrecht AM; Joubert AM
Biomed Res Int; 2019; 2019():1850462. PubMed ID: 31886177
[TBL] [Abstract][Full Text] [Related]
25. BRD4 Connects Enhancer Remodeling to Senescence Immune Surveillance.
Tasdemir N; Banito A; Roe JS; Alonso-Curbelo D; Camiolo M; Tschaharganeh DF; Huang CH; Aksoy O; Bolden JE; Chen CC; Fennell M; Thapar V; Chicas A; Vakoc CR; Lowe SW
Cancer Discov; 2016 Jun; 6(6):612-29. PubMed ID: 27099234
[TBL] [Abstract][Full Text] [Related]
26. Selective inhibition of tumor oncogenes by disruption of super-enhancers.
Lovén J; Hoke HA; Lin CY; Lau A; Orlando DA; Vakoc CR; Bradner JE; Lee TI; Young RA
Cell; 2013 Apr; 153(2):320-34. PubMed ID: 23582323
[TBL] [Abstract][Full Text] [Related]
27. The malignant brain tumor (MBT) domain protein SFMBT1 is an integral histone reader subunit of the LSD1 demethylase complex for chromatin association and epithelial-to-mesenchymal transition.
Tang M; Shen H; Jin Y; Lin T; Cai Q; Pinard MA; Biswas S; Tran Q; Li G; Shenoy AK; Tongdee E; Lin S; Gu Y; Law BK; Zhou L; Mckenna R; Wu L; Lu J
J Biol Chem; 2013 Sep; 288(38):27680-27691. PubMed ID: 23928305
[TBL] [Abstract][Full Text] [Related]
28. Oncogenic super-enhancers in cancer: mechanisms and therapeutic targets.
Bacabac M; Xu W
Cancer Metastasis Rev; 2023 Jun; 42(2):471-480. PubMed ID: 37059907
[TBL] [Abstract][Full Text] [Related]
29. Another tie that binds the MTA family to breast cancer.
Kumar R
Cell; 2003 Apr; 113(2):142-3. PubMed ID: 12705862
[TBL] [Abstract][Full Text] [Related]
30. Functional interaction of histone deacetylase 5 (HDAC5) and lysine-specific demethylase 1 (LSD1) promotes breast cancer progression.
Cao C; Vasilatos SN; Bhargava R; Fine JL; Oesterreich S; Davidson NE; Huang Y
Oncogene; 2017 Jan; 36(1):133-145. PubMed ID: 27212032
[TBL] [Abstract][Full Text] [Related]
31. C/EBPα creates elite cells for iPSC reprogramming by upregulating Klf4 and increasing the levels of Lsd1 and Brd4.
Di Stefano B; Collombet S; Jakobsen JS; Wierer M; Sardina JL; Lackner A; Stadhouders R; Segura-Morales C; Francesconi M; Limone F; Mann M; Porse B; Thieffry D; Graf T
Nat Cell Biol; 2016 Apr; 18(4):371-81. PubMed ID: 26974661
[TBL] [Abstract][Full Text] [Related]
32. LSD1 activation promotes inducible EMT programs and modulates the tumour microenvironment in breast cancer.
Boulding T; McCuaig RD; Tan A; Hardy K; Wu F; Dunn J; Kalimutho M; Sutton CR; Forwood JK; Bert AG; Goodall GJ; Malik L; Yip D; Dahlstrom JE; Zafar A; Khanna KK; Rao S
Sci Rep; 2018 Jan; 8(1):73. PubMed ID: 29311580
[TBL] [Abstract][Full Text] [Related]
33. H4K12ac is regulated by estrogen receptor-alpha and is associated with BRD4 function and inducible transcription.
Nagarajan S; Benito E; Fischer A; Johnsen SA
Oncotarget; 2015 Mar; 6(9):7305-17. PubMed ID: 25788266
[TBL] [Abstract][Full Text] [Related]
34. Targeting bromodomain-containing protein 4 (BRD4) inhibits MYC expression in colorectal cancer cells.
Otto C; Schmidt S; Kastner C; Denk S; Kettler J; Müller N; Germer CT; Wolf E; Gallant P; Wiegering A
Neoplasia; 2019 Nov; 21(11):1110-1120. PubMed ID: 31734632
[TBL] [Abstract][Full Text] [Related]
35. Mechanism and relevance of EWS/FLI-mediated transcriptional repression in Ewing sarcoma.
Sankar S; Bell R; Stephens B; Zhuo R; Sharma S; Bearss DJ; Lessnick SL
Oncogene; 2013 Oct; 32(42):5089-100. PubMed ID: 23178492
[TBL] [Abstract][Full Text] [Related]
36. TWIST represses estrogen receptor-alpha expression by recruiting the NuRD protein complex in breast cancer cells.
Fu J; Zhang L; He T; Xiao X; Liu X; Wang L; Yang L; Yang M; Zhang T; Chen R; Xu J
Int J Biol Sci; 2012; 8(4):522-32. PubMed ID: 22457607
[TBL] [Abstract][Full Text] [Related]
37. LSD1 inhibition exerts its antileukemic effect by recommissioning PU.1- and C/EBPα-dependent enhancers in AML.
Cusan M; Cai SF; Mohammad HP; Krivtsov A; Chramiec A; Loizou E; Witkin MD; Smitheman KN; Tenen DG; Ye M; Will B; Steidl U; Kruger RG; Levine RL; Rienhoff HY; Koche RP; Armstrong SA
Blood; 2018 Apr; 131(15):1730-1742. PubMed ID: 29453291
[TBL] [Abstract][Full Text] [Related]
38. General mechanism of JQ1 in inhibiting various types of cancer.
Jiang G; Deng W; Liu Y; Wang C
Mol Med Rep; 2020 Mar; 21(3):1021-1034. PubMed ID: 31922235
[TBL] [Abstract][Full Text] [Related]
39. Combined treatment with CBP and BET inhibitors reverses inadvertent activation of detrimental super enhancer programs in DIPG cells.
Wiese M; Hamdan FH; Kubiak K; Diederichs C; Gielen GH; Nussbaumer G; Carcaboso AM; Hulleman E; Johnsen SA; Kramm CM
Cell Death Dis; 2020 Aug; 11(8):673. PubMed ID: 32826850
[TBL] [Abstract][Full Text] [Related]
40. MBD3/NuRD loss participates with KDM6A program to promote DOCK5/8 expression and Rac GTPase activation in human acute myeloid leukemia.
Biswas M; Chatterjee SS; Boila LD; Chakraborty S; Banerjee D; Sengupta A
FASEB J; 2019 Apr; 33(4):5268-5286. PubMed ID: 30668141
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
